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Association between Fusobacterium 
nucleatum and patient prognosis 
in metastatic colon cancer
Jii Bum Lee1,10, Kyung‑A Kim1,10, Ho Yeon Cho2, DooA Kim2, Won Kyu Kim3, Dongeun Yong4, 
Hyukmin Lee4, Sang Sun Yoon2,5,6, Dai Hoon Han7, Yoon Dae Han7, Soonmyung Paik2, 
Mi Jang8,9*, Han Sang Kim1,2* & Joong Bae Ahn1*
Recent evidence suggests that Fusobacterium nucleatum (Fn) is associated with the development and 
progression of colorectal cancer. We aimed to delineate the clinical implications of Fn in metastatic 
colon cancer. We performed quantitative polymerase chain reaction (qPCR) using DNA samples from 
synchronous metastatic colon cancer patients with either formalin‑fixed paraffin‑embedded (FFPE) 
archival primary site tumor samples or fresh colon tissues. Progression‑free survival (PFS)1 and 
PFS2 were defined as PFS of first‑ and second‑line palliative settings. qPCR for Fn was successfully 
performed using 112 samples (FFPE, n = 61; fresh tissue, n = 51). Forty‑one and 68 patients had right‑
sided and left‑sided colon cancer, respectively. Patients with Fn enriched right‑sided colon cancers 
had shorter PFS1 (9.7 vs. 11.2 months) than the other subgroups (HR 3.54, 95% confidence interval 
[CI] 1.05–11.99; P = 0.04). Fn positive right‑sided colon was also associated with shorter PFS2 (3.7 
vs. 6.7 months; HR 2.34, 95% CI 0.69–7.91; P = 0.04). In the univariate analysis, PFS1 was affected 
by differentiation and Fn positive right‑sided colon cancer. The multivariate analysis showed that 
differentiation (HR 2.68, 95% CI 1.40–5.14, P = 0.01) and Fn positive right‑sided colon (HR 0.40, 95% CI 
0.18–0.88, P = 0.02) were associated with PFS1. Fn enrichment in right sided colon was not associated 
with overall survival (OS). Fn enrichment has significantly worse prognosis in terms of PFS1 and PFS2 
in patients with right‑sided metastatic colon cancers.
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third cause of cancer-related 
 deaths1. In patients with stage IV colon cancer, up to 65% of patients experience recurrence after surgical 
 resection2. The palliative aim of chemotherapeutic agents such as oxaliplatin and irinotecan in the 5-fluoro-
uracil (5-FU) combination with or without targeted agents has improved median  survival3–5. Despite systemic 
treatments with these agents, most patients experience disease progression due to resistance to chemotherapies 
and targeted  agents6. The 5-year survival rate in patients with stage IV colon cancer is less than 10%7. Therefore, 
there is a need for a better understanding of the mechanisms of chemoresistance and the development of treat-
ment options in metastatic and recurrent CRC.
Approximately 16% of cancer development is associated with infectious  agents8. Recently, growing evidence 
from pre-clinical results showed that the gut microbiome has multiple effects on cancer development, progres-
sion, and treatment resistance. Notably, cancer development, and progression of CRC are associated with Fuso-
bacterium nucleatum (Fn), a gram-negative anaerobe found to be enriched in both primary colon cancer and 
distant metastatic  sites9–12. Clinically, Fn infection is associated with decreased T-cell infiltration, BRAF muta-
tion, tumor-infiltrating macrophages, and microsatellite instability-high (MSI-H)13–16. Moreover, an increased 
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amount of Fn also correlates with poor overall survival (OS) in advanced stages and is more prevalent in the 
right-sided  colon17,18.
Several mechanisms of Fn’s role in chemoresistance in CRC have been suggested in pre-clinical  models19. Fn 
promotes carcinogenesis through surface adhesion virulence factors such as FadA and Fap2, which inhibit the 
activity of immune  cells20,21. Furthermore, Fn harbors chemoresistance by modulating the autophagy pathway by 
targeting innate immune  signaling11. Despite these findings, the role of Fn on chemoresistance remains elusive 
in the clinical setting.
In this study, we aimed to delineate the clinical implications of Fn in patients with synchronous metastatic 
colon cancer. To this end, we used surgical specimens to perform quantitative polymerase chain reaction (qPCR), 
detect Fn, and analyze the prognostic role of Fn. We determined whether Fn enrichment by primary tumor loca-
tion (left-sided vs. right-sided) was correlated with patient prognosis.
Results
Baseline characteristics according to Fn enrichment. Among the patients with synchronous meta-
static colon cancer, qPCR was successfully performed using 112 patient colon tumor samples, including 61 FFPE 
and 51 fresh tissue samples. We also analyzed fresh tumor specimens with adjacent normal tissue (n = 34), as 
shown in Fig. 1. Compared to adjacent normal tissues, tumor tissues had four times higher level of Fn (P = 0.01).
Baseline patient characteristics with both Fn enriched (n = 44) and Fn negative (n = 68) metastatic colon 
cancer are shown in Table 1. Patients with right-sided colon cancer accounted for 37% (n = 41), and major-
ity were diagnosed with left-sided colon cancer (n = 68, 61%). Most of the patients were classified as having 
adenocarcinoma (n = 108, 96%). The moderately differentiated (MD, n = 74, 66%) grade was the most common 
pathologic differentiation, followed by the well- (WD, n = 25, 22%) and poorly (PD, n = 13, 12%) differentiated 
grades. The KRAS, NRAS, and BRAF mutations were not significantly different between the two subgroups, with 
P-values of 0.77 and 0.58, respectively. There was also no difference in microsatellite status between the two 
groups (P = 0.13), although only 50 patients (45%) had results for evaluation. Most patients had three or more 
metastatic sites (n = 98, 87%) prior to palliative systemic chemotherapy. Fifteen patients (13%) did not receive 
palliative chemotherapy. Among the patients treated in first-line palliative setting, most patients (n = 66, 59%) 

















































Figure 1.  Relative amount of Fusobacterium nucleatum (Fn) in the tumor (n = 34, ΔCT mean: 8.47) tissue and 
adjacent normal (n = 51, ΔCT mean: 10.36) tissues. Asterisk indicates significant differences between the ΔCT 
mean of the tumor and adjacent normal tissues (*P < 0.05).
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infused fluorouracil with oxaliplatin; n = 24, 21%;), and others (n = 7, 7%) which included investigational agents 
(n = 2), capecitabine (n = 2), CAPOX (capecitabine combined with oxaliplatin; n = 1), and 5-FU infusion with 
leucovorin (n = 1). Most of the patients were not treated with targeted agents (n = 74, 66%). Bevacizumab was 
administered to 32 patients (29%) and cetuximab to 6 patients (5%). Overall, there were no identifiable factors 
that differed between the two groups. Second and third-line chemotherapy was administered to 61 (54%) and 
Table 1.  Baseline characteristics of patients. WD well differentiated, MD moderately differentiated, PD poorly 
differentiated, MSI-H microsatellite instability-high, MSS microsatellite stable, FOLFOX bolus and infused 
fluorouracil with oxaliplatin, FOLFIRI bolus and infused fluorouracil with irinotecan.
Fusobacterium nucleatum
Total Negative Positive P value
Number of patients 112 68 44
Age (years)
< 65 49 (44%) 32 (65%) 17 (35%)
0.44
≥ 65 63 (56%) 36 (57%) 27 (43%)
Sex
Male 66 (59%) 39 (59%) 27 (41%)
0.7
Female 46 (41%) 29 (63%) 17 (37%)
Location
Right 41 (37%) 30 (73%) 11 (27%)
0.09Left 68 (61%) 37 (54%) 31 (46%)
Both right and left 3 (2%) 1 (33%) 2 (67%)
Histology
Adenocarcinoma 108 (96%) 65 (60%) 43 (40%)
0.99
Mucinous 4 (4%) 3 (75%) 1 (25%)
Differentiation
WD 25 (22%) 16 (64%) 9 (36%)
0.77MD 74 (66%) 43 (58%) 31 (42%)
PD 13 (12%) 9 (69%) 4 (31%)
KRAS/NRAS
Mutated 35 (31%) 21 (60%) 14 (40%)
0.77Wild type 61 (54%) 36 (59%) 25 (41%)
NA 16 (15%) 11 (69%) 5 (31%)
BRAF
Mutated 5 (4%) 2 (40%) 3 (60%)
0.58Wild 98 (88%) 61 (62%) 37 (38%)
NA 9 (8%) 5 (56%) 4 (44%)
Microsatellite status
MSI-H 1 (1%) 0 (0%) 1 (100%)
0.13MSS 49 (44%) 26 (53%) 23 (47%)
NA 62 (55%) 42 (68%) 20 (32%)
Number of metastatic sites
< 2 14 (13%) 7 (50%) 7 (50%)
0.4
≥ 3 98 (87%) 61 (62%) 37 (38%)
First-line palliative chemotherapy
FOLFOX 24 (21%) 13 (54%) 11 (46%)
0.80
FOLFIRI 66 (59%) 40 (61%) 26 (39%)
Others 7 (7%) 5 (71%) 2 (39%)
None 15 (13%) 10 (67%) 5 (33%)
First-line targeted agents
Bevacizumab 32 (29%) 19 (59%) 13 (41%)
0.83Cetuximab 6 (5%) 3 (50%) 3 (50%)
None 74 (66%) 46 (62%) 28 (38%)
Subsequent chemotherapy
Second line 61 (54%) 24 (39%) 37 (61%)
0.506
Third line 31 (28%) 10 (32%) 21 (68%)
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31 patients (28%), respectively. The median follow-up duration after the initial diagnosis was 2.2 years. At the 
time of analysis, 71 patients (63%) were deceased.
Fn and patient prognosis in metastatic colon cancer. We examined whether progression-free sur-
vival (PFS) and overall survival (OS) differed between subgroups to test our hypothesis whether enrichment in 
Fn by tumor location (right- and left-sidedness) had prognostic implications in metastatic and recurrent colon 
cancer. PFS1, PFS2, and PFS3 were defined as PFS of first-, second-, and third-line palliative treatment settings. 
The subgroups were categorized according to Fn enrichment and primary tumor location (right or left-sided-
ness). Synchronous right- and left-sided colon cancers (n = 3, 2%) were excluded from the analysis.
Patients with Fn enriched right-sided colon cancers (n = 11) had shorter median PFS1(mPFS1) than other sub-
groups did (9.7 vs. 11.2 months, respectively, HR 3.54, 95% CI 1.05–11.99; P = 0.04) (Fig. 2A). Other subgroups 
(n = 98) included Fn negative, right-sided colon cancer (n = 30), Fn enriched, left-sided colon cancer (n = 31), 
and Fn negative, left-sided colon cancer (n = 37). Subsequently, 59 and 30 patients received second and third 
line palliative chemotherapy, respectively. Patients with Fn enriched right-sided colon cancers (n = 6) also had 
shorter median PFS2 (mPFS2) compared to other subgroups (n = 53) (3.7 vs. 6.7 months, respectively, HR 2.34, 
95% CI 0.69–7.91; P = 0.04) (Fig. 2B). There was no statistical significance in median PFS3 (mPFS3) between Fn 
enriched right-sided colon cancers (n = 4) and other subgroups (n = 26) (Fig. 2C). Although there was a trend for 
shorter median OS (mOS) of 3.2 years in Fn enriched right-sided colon cancers compared to other subgroups 
with a mOS of 4 years, there was no statistical significance between the two groups (hazard ratio [HR] 1.10, 95% 
confidence interval [CI] 0.48–2.51; P = 0.82) (Fig. 2D).
We then compared mPFS1, mPFS2, mPFS3, and mOS among the four groups (Supplementary Fig. S1A). 
Fn-enriched right-sided colon cancers had the shortest mPFS1 of 9.7 months, whereas Fn-enriched left-sided 
colon had the longest mPFS1 of 14.5 months (P = 0.02). Although the difference in mPFS1 was not statistically 
significant (P = 0.20), the mPFS1 in patients with Fn negative right-sided colon cancer (10.4 months) was com-
parable to that in patients with left-sided colon cancer without Fn enrichment (10.2 months). Similar trends were 
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Figure 2.  Kaplan–Meier curves of progression-free survival (PFS) in the (A) first (PFS1)-, (B) second (PFS2)-, 
(C) third (PFS3)-line palliative treatment, and (D) overall survival (OS) for Fn enriched, right-sided colon 
versus others. Others include (1) Fn enriched, left-sided colon cancer, (2) Fn negative, right-sided colon cancer, 
and (3) Fn negative, left-sided colon cancer.
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seen in mPFS2 (P = 0.19) and mPFS3 (P = 0.48), with Fn-enriched right-sided colon cancers with the shortest 
PFS, but the results were not statistically significant (Supplementary Fig. S1B,C).
Patients were also categorized according to first-line palliative treatment received and were grouped as (1) 
Fn enriched, FOLFIRI-treated colon cancer, (2) Fn negative, FOLFIRI-treated colon cancer, (3) Fn enriched, 
FOLFOX-treated colon cancer, and (4) Fn negative, FOLFOX-treated colon cancer (Supplementary Fig. S2A,B). 
Although Fn negative, FOLFOX treated colon cancer had the shortest PFS and OS, there was no statistical dif-
ference of PFS1 (P = 0.34) and OS (P = 0.23) among the subgroups. Patients with Fn enriched right-sided colon 
cancer had the shortest OS of 3.2 years, followed by patients with Fn enriched left-sided colon cancer (3.7 years), 
Fn negative right-sided colon cancer (3.9 years), and Fn negative left-sided colon cancer (4.1 years). Overall, the 
mOS was similar across all subgroups (P = 0.99) (Supplementary Fig. S1D).
Univariate and multivariate analyses of factors affecting survival. We performed a univariate 
analysis of the factors affecting PFS1 and OS. The univariate analysis of PFS1 showed that tumor differentiation 
(HR 0.89, 95% CI 9.46–12.94, P = 0.02) and Fn positive right-sided colon cancer (HR 4.80, 95% CI 0.32–19.15, 
P = 0.02) were associated with worse PFS (Table 2). The multivariate analysis further showed that both differ-
entiation (HR 2.68, 95% CI 1.40–5.14, P = 0.01) and Fn positive right-sided colon cancer (HR 0.40, 95% CI 
0.18–0.88, P = 0.02) were significant determinants of PFS1. In both univariate and multivariate analyses, Fn 
enriched right-sided colon cancer was not an independent risk factor of OS (Supplementary Table 1). Tumor dif-
ferentiation was an independent factor in both univariate (HR 1.31, 95% CI 1.57–6.73) and multivariate analyses 
(HR 4.00, 95% CI 0.18–0.88, P = 0.02).
Validation in The Cancer Genome Atlas (TCGA) metastatic colon cancer. Next, we applied our 
findings to a large cancer genome cohort as independent  validation22. In the TCGA colon cancer cohort, a total 
of 53 patients was stage IV metastatic colon cancer. Consistent with our finding, patients with Fn enriched right-
sided colon cancers (n = 7) had shorter median PFS1 (mPFS1) than other subgroups did (8.5 vs. 20.4 months; 
HR 6.3, 95% CI 1.59–25.08; log-rank test, P = 0.008) (Fig.  3A and Supplementary Fig.  S3A). Furthermore, 
patients who harbor Fn enriched right-sided colon cancers (n = 7) were significantly associated with shorter 
Table 2.  Univariate and multivariate analyses of progression-free survival (PFS)1 in the first-line treatment. 
WD well differentiated; MD moderately differentiated; PD poorly differentiated; PFS1 progression-free 
survival1; Fn, Fusobacterium nucleatum; HR hazard ratio, CI confidence interval.
Variables Category
Univariate Multivariate
HR 95% CI P HR 95% CI P
Age < 65 vs. ≥ 65 years 0.82 9.59–12.81 0.63
Differentiation WD, MD vs. PD 0.89 9.46–12.94 0.02 2.68 1.40–5.14 0.01
Number of metastatic sites < 2 vs. ≥ 3 4.89 0–18.96 0.86
Fn positive, right-sided colon vs. others 4.80 0.32–19.15 0.02 2.51 1.14–5.56 0.02
















































Figure 3.  Kaplan–Meier curves of (A) progression-free survival (PFS) and (B) overall survival (OS) for Fn 
enriched, right-sided colon versus others in the validation cohort using The Cancer Genome Atlas (TCGA) 
colon cancer data. Others include (1) Fn enriched, left-sided colon cancer, (2) Fn negative, right-sided colon 
cancer, and (3) Fn negative, left-sided colon cancer.
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OS (8.4 months vs. 3.6 years; HR 4.6, 95% CI 1.10–19.19; log-rank test, P = 0.036) (Fig. 3B and Supplementary 
Fig. S3B).
Discussion
The gut microbiome affects carcinogenesis, progression, and response to treatment in CRC 19. Among diverse 
microbiomes, Fn is one of the most commonly found in tissue samples of colon cancers and contributes to 
 chemoresistance11,23. Similarly, our study showed that Fn was enriched four-fold higher in colon tissues than in 
normal adjacent tissues. Fn enriched right-sided colon cancer was associated with a poor prognosis in terms of 
mPFS. In contrast, Fn negative right-sided colon cancer had comparable mPFS and mOS with left-sided colon 
cancer. In addition to the tumor right-sidedness, Fn positivity contributed to the lack of response to systemic 
chemotherapy in palliative settings. Collectively, these findings suggest that Fn contributes to chemoresistance 
and may be a potential predictive or prognostic biomarker in metastatic and recurrent rectal cancer.
Although the previous report suggests that the amount of tissue Fn was associated with poor cancer-specific 
 mortality17,24, the data on cancer treatment were limited, and the role of Fn on chemoresistance was not addressed 
in clinical samples. Therefore, our study tried to add a missing link between chemoresistance of Fn in preclinical 
 studies11,23 and the clinical validation. Considering that the development of chemoresistance is a critical issue 
in metastatic colon cancer, we focused on synchronous metastatic colon cancer patients. We showed shorter 
PFS1 and PFS2 in metastatic patients than other reports with heterogeneous colorectal cancer patients with all 
tumor  stages17,24.
Several studies have shown that primary tumor location affected prognosis in patients with right-sided colon 
cancer having worse prognosis in recurrent and metastatic  settings25,26. Fn has been found in abundance in proxi-
mal locations such as cecum, ascending, and transverse colon compared to distal locations, including sigmoid 
colon and  rectum18. One potential mechanism underlying chemoresistance to 5-FU and oxaliplatin is the ability 
of Fn to target innate immune signaling pathways such as Toll-like receptor 4 (TLR4) and activating Myeloid 
differentiation primary response 88 (MyD88) in cancer cells to activate autophagy  pathway11. The abundance 
and negative prognostic implications of Fn in right-sided colon cancer warrant treatment strategies specifically 
targeting Fn. Treatment with metronidazole for Fn enriched patient-derived xenograft showed a decrease in 
both the amount of Fn and tumor  growth12. However, metronidazole does not target only Fn but also normal 
anaerobes in the intestines, which may disrupt the composition of normal  flora27. Thus, Fn-specific treatment 
with antimicrobial agents is limited in practicality.
The presence of Fn is associated with microsatellite instability (MSI-high) and shorter  survival13,14,17,28. Two 
virulence factors, Fap2 and FadA, have been identified as potential immune  modulators20,21. Fap2 protein binds 
to T cell immunoreceptor with Ig and ITIM domain and suppresses natural killer cell  cytotoxicity21. FadA binds 
to vascular endothelial cadherin (CDH5) and E-cadherin20. The binding to CDH5 receptors activates the inflam-
matory genes of NF-κB and cytokines, and the binding to E-cadherin expressed on colon cells activates Wnt 
genes and oncogenes, thereby promoting an immune-suppressive environment.
Until recently, the current standard of palliative treatment in colon cancer was limited to cytotoxic agents 
with targeted agents such as cetuximab and  bevacizumab5. Recently, an anti-PD-1 agent pembrolizumab showed 
superior efficacy in MSI-H/mismatch repair deficient metastatic CRC based on the pivotal Keynote-177  trial29. 
The study demonstrated the doubling of PFS in response to pembrolizumab compared to standard chemotherapy 
with or without bevacizumab or  cetuximab29. Although MSI-H incidence in metastatic CRC setting is less than 
5%, pembrolizumab is a promising new standard of treatment option for this subset of  patients30. Whether 
treatment with immune checkpoint inhibitors such as pembrolizumab is more effective in Fn enriched colon 
cancer harboring MSI-H and whether changes in enrichment status of Fn are evident after immunotherapy are 
interesting questions to be studied in the future. In our study, 55% of patients did not have MSI status because we 
retrospectively reviewed and included surgical specimens that date back to the time when MSI was not performed 
routinely. Only one patient with MSI-H colon cancer was included and treated with cytotoxic chemotherapy.
Limitations to this study include small sample size and its retrospective nature. Although we collected 112 
tissue samples, further analysis of primary tumor location and Fn positivity resulted in fewer patients and uneven 
distribution in subgroups. Considering shorter PFS in response to palliative chemotherapy and poor prognosis 
of Fn positivity in both our cohort and independent TCGA metastatic colon cancer data, a larger number of 
patients in prospective settings warrants further validation and expansion of our findings.
In conclusion, Fn enriched right-sided metastatic, and recurrent colon cancer was significantly associated with 
worse PFS, indicating that Fn enriched right-sided colon responded less to palliative cytotoxic chemotherapy. 
Further analysis, including more extensive patient sampling and prospective cohort, are needed to validate the 
proposed role of Fn in chemoresistance.
Methods
Study population. From January 2009 to July 2019, data of patients with metastatic and recurrent colon 
cancer in Yonsei Cancer Center, Korea, were collected retrospectively. A total of 112 patients had surgical colon 
specimens available either as Formalin-Fixed Paraffin-Embedded (FFPE) or fresh tissue for analysis of Fn using 
qPCR.
Clinicopathological variables including age, sex, primary tumor location, histology, sites of metastasis, muta-
tions such as KRAS, NRAS, BRAF, and microsatellite status were collected. The staging was determined using the 
8th edition of the American Joint Committee on Cancer guideline of the primary tumor, node, and metastasis 
 classification31. Right-sided colon cancers were defined as tumors occurring from cecum to transverse colon, 
and left-sided colon cancers as tumors arising from splenic flexure to sigmoid  colon26.
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Patients were treated with first-line palliative chemotherapeutic agents such as FOLFOX (5-fluorouracil, 
leucovorin, and oxaliplatin), FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) with or without targeted 
agents such as bevacizumab or cetuximab, CAPEOX (capecitabine and oxaliplatin), and capecitabine. These 
regimens have been described in detail in another  study32. Response evaluation was performed using computed 
tomography scanning every two months, every four cycles for FOLFOX and FOLFIRI, and every three cycles 
for capecitabine.
All authors followed Good Clinical Practice, and the study was conducted according to the principles of the 
Declaration of Helsinki. All enrolled patients provided written informed consent. The protocol was approved 
by the Institutional Review of Severance Hospital (IRB 4-2014-0239).
DNA isolation and quantitative PCR analysis of Fn. Genomic DNA was isolated from clinical sam-
ples using the QIAamp DNA Mini Kit (Qiagen, Crawley, UK). Briefly, the samples were suspended with protease 
K in ATL buffer and incubated at 55 °C for 2 h. Both AL buffer and absolute ethanol were added to the samples 
before applying the QIAamp spin column. Each sample was centrifuged and washed according to the manufac-
turer’s protocol. DNA was eluted from the column with 50 μL of the supplied AE buffer. The quality and quantity 
of the isolated DNA were determined using a NanoDrop spectrophotometer (ND-1000; Thermo Scientific, MA, 
USA).
To detect the Fn sequence, specific primers and probes were designed to recognize the 16S ribosomal RNA 
gene. Amounts of Fn DNA were determined using quantitative real-time PCR using the TaqMan assay system. 
Each reaction was carried out in the final volume of 20 μL reaction containing 1 × TaqMan Universal PCR Master 
Mix (Applied Biosystems, CA, USA), 300 nM of each primer, 200 nM TaqMan probe, and 30 ng of genomic 
DNA in a 96-well optical PCR plate. Amplification, detection, and data analysis were performed using the Ste-
pOnePlus Real-Time PCR Systems (Applied Biosystems, CA, USA) as follows: 10 min pre-incubation at 95 °C, 
amplification cycles of 95 °C for 15 s and 60 °C for 1 min were repeated 50 times. The cycle threshold (Ct) values 
for Fn were normalized to the amount of gDNA in each reaction using prostaglandin transporter (PGT) as a 
human reference gene.
The primer and probe sequences for the TaqMan assay system were as follows: Fn forward primer, 5′-GGA 
TTT ATT GGG CGT AAA GC-3′; Fn reverse primer, 5′-GGC ATT CCT ACA AAT ATC TAC GAA -3′; Fn FAM probe, 
5′-CTC TAC ACT TGT AGT TCC G-3′; PGT forward primer, 5′-ATC CCC AAA GCA CCT GGT TT-3′; PGT reverse 
primer, 5′-AGA GGC CAA GAT AGT CCT GGTAA-3′; PGT FAM probe, 5′-CCA TCC ATG TCC TCA TCT C-3′.
Statistical analysis. For all statistical analysis, differences were considered to be statistically significant 
at P < 0.05. Baseline characteristics were compared using the Kruskal–Wallis test or Mann–Whitney U test. 
Progression-free survival (PFS) was defined as the time from the start of palliative chemotherapy to the date of 
progression, last follow-up, or death. The time points for PFS1, PFS2, and PFS3 were defined as the start of first-, 
second-, and third-line palliative chemotherapy, respectively. OS was calculated from the date of initial diagnosis 
to the date of last follow-up or death. The Kaplan–Meier method was used to estimate median PFS and OS, and 
the Cox proportional hazard model was used for multivariate analysis. All analyses were conducted using SPSS 
statistical software ver. 25 (IBM, Chicago, IL, USA) and GraphPad Prism 8 (GraphPad Software, Inc., San Diego, 
CA).
Data availability
The datasets used or analyzed from this trial may be available upon reasonable request to the corresponding 
author.
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